EGFR and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR) mutation demonstrates increased sensitivity to the anti-EGFR tyrosine kinase inhibitors (TKIs) [1].